Adaptimmune Therapeutics PLC · OTC:ADAPY
Adaptimmune Therapeutics — Investor Presentation (September 2015)
30 slides from Adaptimmune Therapeutics's investor presentation, Sep 15, 2015
Slide 1: Engineered TCR T cell therapy Presentation Materials September 2015
Adaptimmune Engineered TCR T cell therapy Presentation Materials September 2015
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and o
Slide 3: Investment Highlights
Investment Highlights Focused on engineered T cell receptors (TCR) for autologous T cell therapeutics to treat cancer Lead clinical candidate, NY-ESO T-cell therapeutic, is in multiple human studies and has shown efficacy in solid tumours and haematologic cancer types Synovial sarcoma – 6 responses
Slide 4: TCR Platform built up over years
TCR Platform built up over 15 years 1999-2006 Avidex formed on basis of TCR technology from Oxford University Acquired by Medigene (2006) 2008 Adaptimmune formed as a virtual company with UPenn collaboration 2011-2014 Adaptimmune establishes R&D infrastructure and delivers promising clinical data 20
Slide 5: Experienced Management Team and Board
Experienced Management Team and Board Executive Management Name: Title: Experience: James Noble, MA, FCA CEO & Co-Founder Helen Tayton-Martin, PhD MBA COO & Co-Founder Adrian Rawcliffe CFO Rafael Amado, MD CMO Gwen Binder-Scholl, PhD EVP, Adaptimmune LLC Board of Directors Name: Affiliation: Experie
Slide 6: TCRs recognise intracellular cancer antigens
TCRs recognise intracellular cancer antigens The TCR is the natural mechanism for T cells to distinguish a diseased cell from a healthy cell All proteins, including intracellular ones, are processed and presented as HLA-peptide complexes which are recognized by TCRs Many cancer targets are intracell
Slide 7: Autologous T cell therapy
Autologous T cell therapy Blood is taken from a patient, including cells from the immune system Adaptimmune modifies cells from the immune system with enhanced T cell receptors (TCRs) The cells are grown and re-infused to the patient The engineered cells then find and destroy cancer cells Patient Ap
Slide 8: Robust Pipeline of T-Cell Receptors
NY-ESO TCR MAGE A10 TCR 12 Research Programs 20+ Validated Targets NSCLC Other solid tumors TCR Candidate Rights Research Pre-IND Phase 1/2 Comments First cohort completed Two further cohorts enrolling 1st trial published in NMED 2nd trial (no auto SCT) in 2016 Continuing enrollment Initiating in 20
Slide 9: Large un-partnered pipeline with ability to target almost all major tumors
Large un-partnered pipeline with ability to target almost all major tumors Adaptimmune GSK 20+ Additional validated targets Twelve new targets selected for development Not yet nominated; programs with work ongoing are excluded Pool of 3: ADAP keeps 2 NY-ESO MAGE-A10 AFP 30+ validated therapeutic tar
Slide 10: Key 2015/2016 Milestones
Key 2015/2016 Milestones YTD and Anticipated Q1 2015 Additions to Adaptimmune senior leadership team April 2015 AACR presented full cohort data for NY-ESO in Sarcoma and MM May 2015 IPO raises $176m net proceeds Q2 2015 Filing and acceptance of IND for Phase 1/2 studies for MAGE A-10 Q3 2015 Publica
Slide 11: Platform and Differentiation
Platform and Differentiation
Slide 12: Adaptimmune: The Leader in TCR T-cell Therapy
Adaptimmune: The Leader in TCR T-cell Therapy Proprietary Technology TCR Engineering Safety Testing Robust Manufacturing Target Validation TCR Gene Delivery T-Cell Isolation T-Cell Expansion Multiple, soluble TCRs Potent and specific Enhanced TCRs Enhanced TCRs Molecular analysis Human Cell testing
Slide 13: Integrated TCR Discovery and Development Platform
Integrated TCR Discovery and Development Platform Enables ADAP to identify real cancer targets and to engineer and develop T-cell therapeutics against those targets Protected by a combination of patents and know-how Highly differentiated among peers 7. In house R&D and IP 1. Target identification an
Slide 14: NY-ESO in Synovial Sarcoma
NY-ESO in Synovial Sarcoma > Adaptimmune
Slide 15: Synovial Sarcoma
Synovial Sarcoma Develops from soft tissues such as muscle, or deep skin tissues Generally incurable - 75% to 80% of patients do not survive past two to three years First line therapy - radiotherapy and chemotherapy, surgical resection where possible FDA granted approval for marketing of Votrient® (
Slide 16: ADAP Phase I/II Study in Synovial Sarcoma
ADAP Phase I/II Study in Synovial Sarcoma Multicenter pilot study in 11 patients Objectives include Determine the response rate following NY-ESO-1 Specific T cells Persistence and expansion of engineered T-cells and correlate this with clinical response Patients conditioned with high-dose fludarabin
Slide 17: Synovial Sarcoma: Encouraging Response Rate, Tolerability and Persistence
Synovial Sarcoma : Encouraging Response Rate, Tolerability and Persistence Of the first 10 patients, six responded: only T-cell technology to show clinical anti-tumor response in a solid tumor One complete response, four partial responses, one response at one month Two non responders potentially und
Slide 18: Synovial Sarcoma: Reduction in tumour volume
***Surgical resection of primary but still with PR of lung lesions ** Progression of disease from nadir or CR resection of NY-ESO+ lung mets # Low cell dose, late cytokine release syndrome with tumor infiltrating NY-ESO-1+ cells, tumor progression Synovial Sarcoma : Reduction in tumour volume % Chan
Slide 19: Radiographic Pseudoprogression and Response of Lung Metastases
ADAP Phase I/II Study in Synovial Sarcoma Radiographic Pseudoprogression and Response of Lung Metastases Baseline: Bilateral Miliary Metastatic disease Day +2: Pseudoprogression due to Immune Infilration Day +101: Complete Response Patient 201 NY-ESO C-Reactive Protein AACR April 2015
Slide 20: Partial Response Followed by Tumor Resection in Sarcoma
NY-ESO TCR T cells administered ADAP Phase I/II Study in Synovial Sarcoma Partial Response Followed by Tumor Resection in Sarcoma One month post NY-ESO TCR T cells Two months post NY-ESO T cells Source: Merchant, CTOS, 2014 ~ 70% reduction in lesion size at 2 months after administration of NY-ESO T-
Slide 21: NY-ESO in Multiple Myeloma
NY-ESO in Multiple Myeloma > Adaptimmune
Slide 22: Multiple Myeloma
Multiple Myeloma Formed by malignant plasma cells in bone marrow US prevalence: 77,600 cases - approximately 27,000 new cases expected in 2015 Average five-year survival rates are estimated to be less than 45 percent Majority of patients treated with chemotherapy eventually relapse and cannot be fur
Slide 23: ADAP Phase I/II Study in Multiple Myeloma: Study Design
ADAP Phase I/II Study in Multiple Myeloma Study Design All enrolled patients (n=25) had symptomatic myeloma with active disease High risk population Average of 3 prior Rx Five patients had prior autologous stem cell transplant 12 with cytogenetic abnormalities, including seven categorized as high-ri
Slide 24: Multiple Myeloma: Response Rate Compared to Published Literature
ADAP Phase I/II Study in Multiple Myeloma Compelling Response Rate Compared to Published Literature Two year overall survival (OS) and progression free survival (PFS) as of April 2015 16/25 patients remain alive; 8/25 remain in remission Median PFS = 19.1 months Median OS = 32.1 months 59 percent (1
Slide 25: Multiple Myeloma: Encouraging Tolerability and Persistence
ADAP Phase I/II Study in Multiple Myeloma Encouraging Tolerability and Persistence Generally well tolerated - all SAEs possibly related to the NY-ESO T-cells resolved No clinically apparent cytokine release syndrome despite high IL-6 levels CAR-Ts have been associated with severe adverse events attr
Slide 26: MAGE A10 Next proprietary target
MAGE A10 Next proprietary target
Slide 27: IND for MAGE A-10 TCR therapeutic filed
IND for MAGE A-10 TCR therapeutic filed Preclinical testing complete NIH RAC approval obtained – March 10, 2015 IND approved – announced July 2, 2015 Initial trial in NSCLC expected to open in 2015 Further indications under consideration: Bladder, Head and Neck, Breast and GI cancers
Slide 28: The GSK Strategic Collaboration
The GSK Strategic Collaboration Announced June 2014 – Up-front payment £25M GSK has option to license NY-ESO at end of Phase 1/2 studies Adaptimmune conducts all clinical and non-clinical development work Enables Adaptimmune to optimize regulatory, vector, cell processing, analytical, automation, di
Slide 29: Adaptimmune summary
Adaptimmune (NASDAQ: ADAP) Clinical stage biopharmaceutical company located in Oxfordshire, UK and Philadelphia, PA Well capitalized with 70.8M shares outstanding: ~$300M pro forma cash in F1 Developing engineered T-cell receptors (TCRs) to target cancer cells which the natural immune system cannot
Slide 30: Engineered TCR T cell therapy Presentation Materials September 2015
Adaptimmune Engineered TCR T cell therapy Presentation Materials September 2015
Adaptimmune Therapeutics — Investor Presentation (September 2015) on 6ix